US$ 22.56
jp morgan glp-1 JPM 2026] D&D Pharmatech chose MASH strategy different from Wegovy and Mounjaro < Pharma < Article Unpacking the GLP-1 Hype
Description
The United States Food and Drug Administration (FDA) has not yet issued any warnings related to serious side effects from the use of the brand-name medications Ozempic and Wegovy
![jp morgan glp-1 JPM 2026] D&D Pharmatech chose MASH strategy different from Wegovy and Mounjaro < Pharma < Article Unpacking the GLP-1 Hype](https://i.ytimg.com/vi/LgOYS-YeBvc/oar2.jpg?sqp=-oaymwEYCJUDENAFSFqQAgHyq4qpAwcIARUAAIhC&rs=AOn4CLDfPmCeJ9SdXwQKeJxHBF3gE95hwQ&usqp=CCk)
J med virol
![jp morgan glp-1 JPM 2026] D&D Pharmatech chose MASH strategy different from Wegovy and Mounjaro < Pharma < Article Unpacking the GLP-1 Hype](https://image.cnbcfm.com/api/v1/image/107393750-1711561383116-gettyimages-88296329-ti0300206.jpeg?v=1759260598&w=1200&h=1200)
Diabetes Patients Also Struggle to Access GLP-1 Agonists
J Cell Biochem 123(12):18791890 Yaribeygi H, Maleki M, Butler AE, Jamialahmadi T, Sahebkar A (2021) The impact of incretin-based medications on lipid metabolism